There are no pharmacokinetic data regarding the use of REZOLSTA in patients with hepatic impairment. Use with caution. Monitor for fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. Based on theoretical considerations co administration of REZOLSTA with ticagrelor may increase concentrations of ticagrelor.

When didanosine is co-administered with REZOLSTA, didanosine should be administered on an empty stomach 1 hour before or 2 hours after REZOLSTA (which is administered with food). But keep in mind that solar panels generate most of their electricity during the day, so you may not be around to use it (unless you fit a home storage battery too). In fact, our survey of solar panel owners* found that: Based on theoretical considerations REZOLSTA is expected to increase rilpivirine plasma concentrations. Rash occurred more commonly in treatment-experienced patients receiving regimens containing darunavir/ritonavir + raltegravir compared to patients receiving darunavir/ritonavir without raltegravir or raltegravir without darunavir/ritonavir (see section 4.8).If REZOLSTA is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of REZOLSTA with food as soon as possible. If this is noticed later than 12 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule. To ensure administration of the entire dose of both darunavir and cobicistat, the tablet should be swallowed whole. For patients unable to swallow the whole tablet, REZOLSTA may be split into two pieces using a tablet-cutter, and the entire dose should be consumed immediately after splitting. Monitoring of renal function may be indicated when REZOLSTA is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents. Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients

Concomitant use of REZOLSTA and corticosteroids (all routes of administration) that are metabolised by CYP3A may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. Based on theoretical considerations REZOLSTA is expected to increase these anti-depressant plasma concentrations. In some cases, a child may be infected with the virus and never develop the rash. Less commonly, the rash may appear without a preceding fever. In most cases, particularly if fever is low, the child is well. In about 5–15% of young children, high fevers may trigger febrile seizures. How is roseola diagnosed?Cobicistat has no detectable antiviral activity against HIV-1 and does not antagonise the antiviral effect of darunavir. Before you invite any solar panel firms to give you a quote, consider what type of solar PV systems you want.

When REZOLSTA is co-administered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia. Solar panel system sizes are normally expressed in kilowatt peaks (kWp), which is the maximum output of the system. Darunavir and cobicistat are metabolised by the hepatic system. Separate trials of darunavir/ritonavir and cobicistat suggest no dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, REZOLSTA should be used with caution in these patients.In the virologic failures of the GS-US-216-130 trial no cross-resistance with other HIV PIs was observed. Refer to the table above for information on ARTEMIS and ODIN. Based on theoretical considerations efavirenz is expected to decrease darunavir and/or cobicistat plasma concentrations. Co-administration of amiodarone, bepridil, dronedarone, ivabradine, quinidine, or ranolazine and REZOLSTA is contraindicated (see section 4.3). Co-administration with CYP3A-metabolised corticosteroids is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid effects.

Alternative corticosteroids which are less dependent on CYP3A metabolism e.g. beclomethasone should be considered, particularly for long term use. Efficacy of darunavir 800 mg once daily co- administered with 100 mg ritonavir once daily in ART-naïve patients Prices vary during the year. For example, between May 2020 and April 2021, prices per kW were highest in April, May and February and lowest between August and October, according to BEIS. Voriconazole should not be combined with REZOLSTA unless an assessment of the benefit/risk ratio justifies the use of voriconazole. REZOLSTA should not be used concurrently with products or regimens containing ritonavir or cobicistat. REZOLSTA should not be used in combination with the individual components of REZOLSTA (darunavir or cobicistat). REZOLSTA should not be used in combination with another antiretroviral that requires pharmacoenhancement since dosing recommendations for such combination have not been established.Concomitant use of PDE-5 inhibitors for the treatment of erectile dysfunction with REZOLSTA should be done with caution. If concomitant use of REZOLSTA with sildenafil, vardenafil or tadalafil is indicated, sildenafil at a single dose not exceeding 25 mg in 48 hours, vardenafil at a single dose not exceeding 2.5 mg in 72 hours or tadalafil at a single dose not exceeding 10 mg in 72 hours is recommended. Darunavir contains a sulphonamide moiety. REZOLSTA should be used with caution in patients with a known sulphonamide allergy. Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4). Once they're installed, your attitudes towards the main benefits of your solar panels might change, but it's worth considering what you are expecting upfront. Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. If switching from ritonavir as a pharmacoenhancer to cobicistat, caution is required during the first two weeks of treatment with REZOLSTA, particularly if doses of any concomitantly administered medicinal products have been titrated or adjusted during use of ritonavir as a pharmacoenhancer.